Despite significant advancements in cancer therapy, the challenge of inhibiting metastasis remains daunting and complex. Our research focuses on a candidate compound identified through a 3D spheroid invasion drug screening as being particularly effective in impeding the invasion of glioblastoma and pancreatic tumor spheroids. We found that this compound, known as a microtubule stabilization agent, disrupts the interactions between the microtubule plus end and the plasma membrane. Furthermore, we confirmed the interaction disruption by monitoring the movement of the microtubule plus tip protein, EB1 (end-binding protein 1). Additionally, through immunofluorescence and label-free imaging, we observed the formation of abnormally large focal adhesions, identified through integrin αvβ3 and paxillin, resulting from impaired focal adhesion disassembly in cells treated with the compound. Further research is required to determine the underlying mechanisms by which the compound inhibits focal adhesion turnover through disrupting the interaction between the microtubule and the plasma membrane. The compound, characterized by its remarkable capacity to suppress invasion and its low toxicity, may is especially effective in the treatment of metastatic cancer.